Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

SAN DIEGO, Calif., Oct. 19, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. Obesity 2009 is one of the largest scientific conferences in the field of obesity.

Amylin will also present new scientific findings from preclinical studies related to its clinical-stage obesity programs for pramlintide/metreleptin and davalintide, an optimized amylin analog. These findings include new insights into the synergistic weight loss observed with various dual-hormone combination regimens. Additionally, Amylin will present at the meeting's pre-conference session focused on obesity pharmacotherapy.

"The discovery of leptin and its role, along with other endocrine signals, in regulating body weight through a neurohormonal feedback system marked the beginning of a new era of obesity research," said Christian Weyer, M.D., vice president, Medical Development at Amylin Pharmaceuticals. "Amylin's unique approach to obesity drug development aims to translate this evolving science into innovative new treatment options and builds on over 20 years of experience in peptide-protein therapeutics."

Key Amylin Activities at Obesity 2009:

Saturday, October 24

  • Pharmacotherapy Update invited presentation: Christian Weyer, M.D., vice president, Medical Development will present at this pre-conference session scheduled from 1:00 - 3:45 p.m. ET.

Sunday, October 25

  • Poster 190-P: "Central Mechanisms Underlying Am
    '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Calif., Jan. 10, 2012  Nine prominent science institutions have ... and careers site for graduate level life science professionals.  ... all among the top graduate programs in the life ... Stony Brook, Louisville, Rochester, University of Texas Medical Branch, ...
... Jan. 10, 2012 The AquaLab Vapor Sorption ... scientists to better understand moisture in products and pinpoint ... by temperature and humidity changes can reveal important details ... type of measurement is called an isotherm.  ...
Cached Medicine Technology:Bio Careers Adds 9 Universities, Reaching 40 Members 2New AquaLab Vapor Sorption Analyzer Puts Isotherm Technology Within Financial Reach of Food and Pharmaceutical Scientists 2
(Date:7/12/2014)... Miami, FL (PRWEB) July 12, 2014 Fresh ... Brazil and Colombia will meet on September 5th at ... allowed the world to see some of the brightest stars ... Diehard soccer fans in Miami will be treated to some ... , Brazil is currently ranked as the third best team ...
(Date:7/12/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
(Date:7/12/2014)... July 12, 2014 The fastest-growing mobile ... test and measurement of LTE networks continues to grow ... for smart devices have increased mobile data traffic, which ... Measurement (CT&M) market. Communications Test and Measurement equipment comply ... , The Communications Test and Measurement Market is estimated ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 ... embarrassing, so one of two inventors from Ashland, Va., ... to do this. "This inspired us to conceive of ... prototype of the patent-pending KIDNEY KOVER, which provides an ... bag. It avoids embarrassment, as well as promotes comfort ...
Breaking Medicine News(10 mins):Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Burn Injuries More Common in Summer 2
... realize international health goals aiming to improve maternal health, ... is crucial. In an editorial published this week entitled ... editors argue that action on maternal health must ... much as it does access to basic medical care. ...
... as hair, nails, sweat glands and mammary glandsare rare ... States, according to a report in the June issue ... JAMA/Archives journals. "Cutaneous appendageal carcinomas are a rare ... that frequently present a diagnostic challenge," the authors write ...
... study in the journal Respirology reveals that ... of chronic obstructive pulmonary disease (COPD) experience longer time ... risk of death, compared to those without diabetes., High ... impairment of immune responses. Researchers led by Dr. Ali ...
... June 21 (HealthDay News) -- Using ear tubes to treat ... a new study finds. , U.S. researchers studied 78 ears ... tubes before cochlear implants. In 46 (59 percent) of the ... In all the other cases, the ear tubes were left ...
... C-section babies seem more likely to develop allergies, ... -- Babies who are born vaginally pick up different ... potentially affecting how their immune systems develop, a new ... insight into why babies born through cesarean sections appear ...
... of an ancient language provides new insights into the ... world. The study, "Dvandvas, Blocking, and the Associative: The ... in the June 2010 issue of the scholarly journal ... Stanford University. A preprint version is available on line ...
Cached Medicine News:Health News:Cancers of sweat glands, other skin-related structures may be increasing in United States 2Health News:Ear Tubes Appear to Be Safe Before Cochlear Implantation 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:The 'bumpy ride' of linguistic change 2
... Donor Screening: The Procleix System ... safety to the nation's blood supply. It ... target capture, and a unique nucleic acid ... HIV-1/HCV Assay can simultaneously detect the presence ...
... Test (Reveal Test) is MedMiras flagship rapid ... human serum or plasma against HIV-1 that ... to HIV infection. The Reveal Test is ... and is comprised of a single-use test ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
X-Hair Trephines...
Medicine Products: